Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy

BACKGROUND: Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The difference in outcome between the three drugs has n...

Descripción completa

Detalles Bibliográficos
Autores principales: Osumi, Hiroki, Shinozaki, Eiji, Ooki, Akira, Wakatsuki, Takeru, Kamiimabeppu, Daisaku, Sato, Taro, Nakayama, Izuma, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877370/
https://www.ncbi.nlm.nih.gov/pubmed/33347731
http://dx.doi.org/10.1002/cam4.3638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877370/
https://www.ncbi.nlm.nih.gov/pubmed/33347731
http://dx.doi.org/10.1002/cam4.3638

Ejemplares similares